- Home
- TULP vs CELU Comparison
TULP vs CELU Comparison
Compare TULP & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TULP | CELU |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 17.3M |
| IPO Year | 2026 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TULP | CELU |
|---|---|---|
| Price | $3.46 | $0.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 3.4K | ★ 39.4K |
| Earning Date | 02-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $18,800,000.00 | ★ $26,550,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $76.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.11 | $0.56 |
| 52 Week High | $4.79 | $4.01 |
Technical Indicators
Market Signals| Indicator | TULP | CELU |
|---|---|---|
| Relative Strength Index (RSI) | 47.95 | 54.13 |
| Support Level | $3.11 | $0.69 |
| Resistance Level | $3.96 | $0.78 |
| Average True Range (ATR) | 0.15 | 0.06 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 52.11 | 52.41 |
Price Performance
Historical ComparisonAbout TULP Bloomia Holdings Inc. Common Stock
Bloomia Holdings Inc is a specialty ag company focused on making and managing its ag investments in the U.S. and internationally. The Company is the majority owner of Bloomia, one of the largest producers of fresh-cut tulips in the United States.
About CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.